ArticleAngiogenesis2026
Neuropilin 1 (NRP1) conveys SEMA3A signals to restrict physiological angiogenesis.
Article in Angiogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The class 3 semaphorin SEMA3A is a secreted glycoprotein that serves as an evolutionary conserved axon repellent with proposed vascular functions. In mice, SEMA3A is dispensable for developmental brain, limb or trunk blood vessel patterning, but restricts vessel branching in the zebrafish embryo trunk. Whereas neuropilin 1 (NRP1) is thought to be the SEMA3A receptor in the mouse, prior reports identified Plexin D1 as the Sema3a receptor in zebrafish trunk vessel patterning, with previous knockdown and knockout studies yielding contradictory results on Nrp1 requirement for vessel patterning in zebrafish. To resolve these discrepancies, we have refined the prior knockdown strategy to limit off target effects and generated mutant zebrafish embryos lacking both Nrp1a and Nrp1b paralogues to show that Nrp1 restricts trunk vessel patterning in a Sema3a-dependent manner. In agreement, we found that NRP1 is required in human endothelial cells for SEMA3A-induced repulsion. Moreover, we show that SEMA3A action via NRP1 does not involve the splicing regulation of FLT1, previously proposed to act downstream of Plexin D1. Instead, sustained NRP1 activation independent of SEMA3A increases the expression of the anti-angiogenic soluble FLT1 (sFLT1), establishing a feedback mechanism to limit endothelial proliferation. Together, these findings demonstrate a dual role for NRP1 in shaping physiological vascular morphogenesis. Thus, NRP1 mediates repulsive SEMA3A cues in endothelial cells, in analogy to its role in axon guidance, and further restricts angiogenesis by promoting the release of sFLT1 in a SEMA3A-independent manner.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.